Compare AIMD & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | BNGO |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.5M |
| IPO Year | N/A | 2018 |
| Metric | AIMD | BNGO |
|---|---|---|
| Price | $1.71 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 22.3K | ★ 107.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.44 | $1.06 |
| 52 Week High | $4.50 | $5.50 |
| Indicator | AIMD | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 62.59 |
| Support Level | $1.63 | $1.09 |
| Resistance Level | $1.84 | $1.33 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 30.36 | 78.20 |
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.